国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01099 国药控股

已收盘 05-04 16:08:22

18.730

+0.260

+1.41%

最高18.940	最低18.590	成交量486.39万
今开18.940	昨收18.470	日振幅1.90%
总市值584.56亿	流通市值251.32亿	总股本31.21亿
成交额9,106万	换手率0.36%	流通股本13.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"国药控股","latestPrice":18.73,"timestamp":1777882102002,"preClose":18.47,"halted":0,"volume":4863888,"delay":0,"changeRate":0.014076881429344969,"floatShares":1341810740,"shares":3121000000,"eps":2.6257944335210763,"marketStatus":"已收盘","change":0.26,"latestTime":"05-04 16:08:22","open":18.94,"high":18.94,"low":18.59,"amount":91056627,"amplitude":0.01895,"askPrice":18.73,"askSize":100800,"bidPrice":18.71,"bidSize":1600,"shortable":3,"etf":0,"ttmEps":2.6257944335210763,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777944600000},"marketStatusCode":5,"adr":0,"listingDate":1253635200000,"exchange":"SEHK","adjPreClose":18.47,"dividendRate":0.039493,"openAndCloseTimeList":[[1777858200000,1777867200000],[1777870800000,1777881600000]],"volumeRatio":0.605199,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK","impliedVol":0.28,"impliedVolPercentile":0.5447},"requestUrl":"/m/hq/s/01099","defaultTab":"news","newsList":[{"id":"1132259822","title":"国药控股2026年第一季度营收178.23亿元，经调整净利润2.80亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132259822","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132259822?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:06","pubTimestamp":1777457189,"startTime":"0","endTime":"0","summary":"国药控股公布2026年第一季度财务数据显示，在报告期内实现营收178.23亿元，同比下降2.57%。同期经调整净利润为2.80亿元，同比下降11.77%。经营现金流净额为-29.35亿元，同比下降61.52%。公司表示，受行业政策调整、市场竞争加剧以及下游回款延迟等因素影响，整体业绩出现一定程度下滑。零售板块方面，实现营收47.39亿元，同比下降4.89%；净利润0.05亿元，同比增长15.42%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630719324","title":"大行评级丨高盛：下调国药控股目标价至19.07港元，预期未来数季收入将逐步复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2630719324","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630719324?lang=zh_cn&edition=full","pubTime":"2026-04-28 14:07","pubTimestamp":1777356421,"startTime":"0","endTime":"0","summary":"高盛发表研报指，国药控股2026年首季销售额约1404亿元，按年微跌0.6%，略低于该行预期，主要由于行业环境持续受压。不过收入趋势自2024年第四季起已出现企稳，该行预期未来几季将逐步复苏，预测今年第二、三、四季销售分别按年跌0.1%、增0.3%及增0.9%。毛利率进一步降至6.44%，反映带量采购(VBP)范围扩大及国家医保目录(NRDL)进一步降价的影响，部分被严格的成本控制所抵销。基于业绩表现，高盛下调国药控股2026至2028年盈利预测3.8%、4.6%及3.5%，以反映销售增长复苏较预期疲弱及对现金循环更保守的假设；目标价由19.83港元下调至19.07港元，评级“中性”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260428/32183540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["EWH","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630321450","title":"大行评级丨花旗：微降国药控股目标价至22.6港元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2630321450","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630321450?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:47","pubTimestamp":1777355221,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指，国药控股2026年首季度收入录1408亿元，按年微跌0.6%，大致符该行预期。按业务划分，管理层指出药品分销业务按年轻微下跌，而医疗器械分销业务的按年跌幅有所收窄，为该业务初步企稳的迹象。较为乐观的是，零售业务年增5%。花旗预期行业整合将持续，国药有望通过持续的城市层面网络扩张，在二三线城市获得市场份额。于药品分销业务持续疲软，花旗下调国药2026至2028年收入预测2%、2%及3%，相应下调同期净利润预测1%、1%及1%，目标价由22.8港元微降至22.6港元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260428/32183469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["EWH","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121740234","title":"异动解读 | 国药控股盘中大跌5.05%，一季度净利润同比下滑近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121740234","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121740234?lang=zh_cn&edition=full","pubTime":"2026-04-27 14:49","pubTimestamp":1777272550,"startTime":"0","endTime":"0","summary":"国药控股今日盘中股价大幅下挫，跌幅达5.05%，引起市场关注。消息面上，公司于今日盘前发布了截至2026年3月31日的第一季度业绩报告。数据显示，公司营业总收入为1407.66亿元人民币，同比微降0.63%；归属于母公司所有者的净利润为14.14亿元人民币，同比减少2.95%，业绩表现承压。国药一致一季度归母净利润同比减少12.36%；国药器械的营业利润同比大幅下滑20.41%。仅有国药股份实现了营收和净利润的同比增长，表现相对稳健。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630193332","title":"国药控股(01099)一季度归母净利润14.14亿元 同比减少2.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630193332","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630193332?lang=zh_cn&edition=full","pubTime":"2026-04-27 07:58","pubTimestamp":1777247936,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)发布截至2026年3月31日止3个月季度业绩，营业总收入1407.66亿元，同比减少0.63%;归属于母公司所有者的净利润14.14亿元，同比减少2.95%;基本每股收益0.45元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110941421","title":"国药控股2026年第一季度营收1407.66亿元，净利润14.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110941421","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110941421?lang=zh_cn&edition=full","pubTime":"2026-04-27 07:42","pubTimestamp":1777246926,"startTime":"0","endTime":"0","summary":"国药控股公布的财报显示，截至2026年3月31日止三个月，集团实现营收1407.66亿元，同比下降0.63%。本期净利润14.14亿元，同比下降2.95%。期内毛利率约为6.65%，去年同期约为6.98%。经营利润率约为2.03%，上年同期为2.07%。财报中未披露具体业务板块的营收增幅及细分数据，公告主要披露了公司整体的营运表现。根据公告，营业成本的减少与销售及管理费用率的总体下降在一定程度上缓解了营收小幅下滑带来的影响；研发投入约为0.03%，相较去年同期也有所下降。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药控股2026年第一季度营收1407.66亿元，净利润14.14亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198138143","title":"国药控股2025年营收微降、母公司溢利保持增长，分销与零售业务协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1198138143","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198138143?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:44","pubTimestamp":1777020250,"startTime":"0","endTime":"0","summary":"在2025年宏观环境总体稳健、医改政策和集采制度不断推进的背景下，国药控股于报告期内实现收入人民币5,751.68亿元，同比相比2024年的5,847.08亿元有所下降，降幅约1.60%。集团整体毛利为416.72亿元，毛利率由上年的7.57%微降至7.25%。总体而言，国药控股在2025年面对行业政策与市场环境变化，收入规模略有回落，但依托成熟的分销网络、零售布局及精细化管理能力，实现母公司持有者应占溢利稳步增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"国药控股2025年营收微降、母公司溢利保持增长，分销与零售业务协同推进","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629688943","title":"国药控股(01099)：国药器械第一季度营业利润2.2亿元 同比减少20.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629688943","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629688943?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:02","pubTimestamp":1776934957,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)发布公司附属公司中国医疗器械有限公司(国药器械)截至2026年3月31日止3个月的财务数据。该公司取得营业收入约170亿元，同比增加1.23%;营业利润2.2亿元，同比减少20.41%;归属于母公司所有者的综合收益1.15亿元，同比减少7.47%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","LU1115378108.SGD","LU0640798160.USD","BK1500","BK1197","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144237355","title":"国药控股2026年第一财季营收170.00亿元，经调整净利润1.15亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144237355","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144237355?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:01","pubTimestamp":1776934881,"startTime":"0","endTime":"0","summary":"本季度信息\n2026年第一财季，国药控股实现营收约170.00亿元，同比增长1.23%。经调整净利润约1.15亿元，同比下降7.47%。同期经营利润约2.20亿元，同比下降20.41%。经营利润率约为1.29%。经营活动产生的现金流量净额为-45.69亿元，较上年同期增长45.86%。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126998584","title":"国药控股第一季度营收135.55亿元，经调整净利润4.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126998584","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126998584?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:12","pubTimestamp":1776859922,"startTime":"0","endTime":"0","summary":"本季度信息\n根据公告显示，国药控股(01099)2026年第一季度实现营业收入约135.55亿元，同比增长6.63%。扣除非经常性损益后，经调整净利润约为4.65亿元，同比增长4.22%。经营活动产生的现金流量净额为-35.93亿元。\n业务分项\n（该财报未披露具体业务板块营收情况。）\n高管解读\n（该财报未披露相关高管言论。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118912962","title":"国药控股2026年第一季度营收178.23亿元，净利润2.80亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118912962","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118912962?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:38","pubTimestamp":1776771493,"startTime":"0","endTime":"0","summary":"根据公告，2026年第一季度国药控股实现营收178.23亿元，同比下降2.57%。扣除非经常性损益后的净利润为2.80亿元，同比下降11.77%。同期营业利润为3.77亿元，同比下降14.24%。收入下滑主要受行业政策变化及市场竞争加剧等因素影响，但公司通过优化业务结构、强化亏损企业治理等措施，削减了人工及租金等刚性费用，带动整体利润降幅相对收窄。分销板块报告期内营收133.56亿元，同比下降1.72%；净利润1.99亿元，同比下降13.60%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184054216","title":"国药控股3月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1184054216","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184054216?lang=zh_cn&edition=full","pubTime":"2026-04-09 06:21","pubTimestamp":1775686888,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司于2026年4月9日披露2026年3月股份变动月报。根据公告，截至2026年3月31日，公司注册股本数额及已发行股份总数均保持稳定，未有新增发行、购回或注销活动。注册股本方面，公司H股注册股本为1,341,810,740股，内资股注册股本为1,778,845,451股，合计3,120,656,191股。报告期内，H股与内资股的数量均未发生变化。公司在报告期内未披露任何股份期权或股权激励计划的变动，也无购回或注销股份的记录。公告由公司秘书吴壹建签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624525647","title":"国药控股等在北京成立供应链公司 注册资本28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624525647","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624525647?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:01","pubTimestamp":1775091660,"startTime":"0","endTime":"0","summary":"人民财讯4月2日电，企查查APP显示，近日，国药（北京）供应链有限公司成立，注册资本28亿元，经营范围包含：供应链管理服务；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广。企查查股权穿透显示，该公司由国药控股等共同持股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023692887288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1115378108.SGD","BK1197","BK1500","LU0640798160.USD","BK1515","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125259337","title":"国药控股2025年度营收73.42亿元，经调整净利润10.96亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125259337","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125259337?lang=zh_cn&edition=full","pubTime":"2026-04-01 22:15","pubTimestamp":1775052948,"startTime":"0","endTime":"0","summary":"本季度信息\n国药控股（股票代码：01099）公布的公告数据显示，截至2025年12月31日止年度，公司实现营收73.42亿元，同比下降1.29%。经调整净利润为10.96亿元，同比上升88.53%。经营活动产生的现金流量净额录得16.39亿元，同比减少49.91%。公告指出，本期净利润显著增长主要因为商誉及无形资产计提减值准备同比减少6.86亿元，同时门店调整带来的人工及租金等刚性费用成本下降所致。\n业务分项\n高管解读","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367","LU1969619763.USD","LU0348766576.USD","LU1115378108.SGD","BK1617","01099","BK1588","06030","06160","IE00BPRC5H50.USD","LU0634319403.HKD","03933","02196","06821","02228","BK1100","01789","BK1593","LU1328615791.USD","LU2399975544.HKD","09926","LU0348783233.USD","01530","LU0307460666.USD","BK0028","LU1303224171.USD","LU1255011170.USD","LU0405327494.USD","09688","BK1191","BK1564","LU2488822045.USD","600030","LU1997245177.USD","LU2495084118.USD","BK1515","BK0276","LU2148510915.USD","LU1770034418.SGD","BK1583","LU2476274308.USD","BK1147","BK1161","LU1719994722.HKD","02268","HK0000165453.HKD","LU0405327148.USD","BK0012","IE00B543WZ88.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623366194","title":"国药控股获Lazard Asset Management LLC增持约209.6万股 每股作价约19.59港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623366194","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623366194?lang=zh_cn&edition=full","pubTime":"2026-03-30 07:38","pubTimestamp":1774827480,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　据香港联交所最新数据显示，3月24日，Lazard Asset Management LLC增持国药控股（01099）209.6025万股，每股作价19.5897港元，总金额约为4106.05万港元。增持后最新持股数目约为1.76亿股，持股比例为13.13%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-30/doc-inhsthzk6657983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0640798160.USD","BK1197","BK1500","LU1115378108.SGD","BK1515","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622806486","title":"国药控股（雄安）有限公司揭牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2622806486","media":"滚动播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622806486?lang=zh_cn&edition=full","pubTime":"2026-03-28 06:47","pubTimestamp":1774651620,"startTime":"0","endTime":"0","summary":"转自：河北日报国药控股（雄安）有限公司揭牌     本报讯3月27日，国药控股（雄安）有限公司揭牌仪式暨健康中国引领下医药行业发展大会在雄安新区举行。国药控股（雄安）有限公司作为集团核心医药商业平台，具备覆盖全国的医药供应链网络和国际领先的物流能力。在雄安自贸试验区管委会的靠前服务、精准对接下，国药控股（雄安）有限公司已于1月19日在雄安自贸大厦完成注册。中国医药集团有限公司负责人说。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-28/doc-inhsnuva4753815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1500","LU1115378108.SGD","01099","BK1515","LU0640798160.USD","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622825483","title":"Lazard Asset Management LLC增持国药控股(01099)约209.6万股 每股作价约19.59港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622825483","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622825483?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:14","pubTimestamp":1774610092,"startTime":"0","endTime":"0","summary":"3月24日，Lazard Asset Management LLC增持国药控股(01099)209.6025万股，每股作价19.5897港元，总金额约为4106.05万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260327/20260327191409_44237.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260327/20260327191409_44237.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01099","BK1197","LU1115378108.SGD","BK1515","BK1500","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622047303","title":"【券商聚焦】华泰研究维持国药控股(01099)“买入”评级 指零售板块领衔增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622047303","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622047303?lang=zh_cn&edition=full","pubTime":"2026-03-25 14:31","pubTimestamp":1774420277,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰研究发布研报指，国药控股 2025年收入为5752亿元人民币，同比下降1.6%，归母净利润为71.6亿元，同比增长1.5%，符合市场预期。展望2026年，随着药品及器械分销业务结构持续优化带动收入企稳，零售板块批零协同深化经营改善，预计公司净利润将继续保持正增长。零售业务2025年收入为384亿元，同比增长6.67%，成为集团领衔增长的板块，经营溢利率提升0.66个百分点至1.56%，主要得益于整体降本增效的费用管控及国大药房显著减亏。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621550420","title":"瑞银：微升国药控股(01099)目标价至25.7港元 预料今年收入增长胜同行","url":"https://stock-news.laohu8.com/highlight/detail?id=2621550420","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621550420?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:30","pubTimestamp":1774333840,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，国药控股(01099)2025年总收入5,751亿元人民币(下同)，同比跌1.6%；股东应占净利润71.6亿元，同比升1.5%，均大致符预期。行业政策逆风持续对分销收入构成压力，但该行认为公司的成本控制和业务优化降低了营运费用率。该行上调2026至2028年每股盈利预测1%至2%，维持“买入”评级，目标价由24.2港元上调至25.7港元。该行预期，公司今年收入增长将快于行业，主要受惠于市场份额提升、创新药分销业务及零售业务，净利润率有望轻微扩张。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":-0.0557},{"period":"1month","weight":-0.0856},{"period":"3month","weight":-0.1154},{"period":"6month","weight":-0.0465},{"period":"1year","weight":0.0474},{"period":"ytd","weight":-0.0499}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药控股股份有限公司是一家主要从事药品、医疗保健产品及医疗器械批发和零售业务的中国公司。该公司通过四个部门运营业务。医药分销部门为国内外药品及保健品制造商及其他供货商提供分销、物流及其他加值服务。器械分销部门向客户分销医疗器材。医药零售业务部门拥有直接经营或特许经营的零售药局网路。其他业务部门从事药品、化学试剂及实验室用品的制造与销售。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.004643},{"month":2,"riseRate":0.588235,"avgChangeRate":0.029413},{"month":3,"riseRate":0.470588,"avgChangeRate":0.007007},{"month":4,"riseRate":0.411765,"avgChangeRate":0.016485},{"month":5,"riseRate":0.625,"avgChangeRate":-0.004548},{"month":6,"riseRate":0.4375,"avgChangeRate":-0.005852},{"month":7,"riseRate":0.5,"avgChangeRate":-0.015111},{"month":8,"riseRate":0.4375,"avgChangeRate":0.012101},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.011177},{"month":10,"riseRate":0.647059,"avgChangeRate":0.042295},{"month":11,"riseRate":0.470588,"avgChangeRate":-0.007287},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.004122}],"exchange":"SEHK","name":"国药控股","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药控股,01099,国药控股股票,国药控股股票老虎,国药控股股票老虎国际,国药控股行情,国药控股股票行情,国药控股股价,国药控股股市,国药控股股票价格,国药控股股票交易,国药控股股票购买,国药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}